(Q36839762)

16 August 2017

1 reference

title

Oblimersen in the treatment of metastatic melanoma (English)

1 reference

16 August 2017

1 reference

Ahmad A Tarhini

1

1 reference

16 August 2017

John M Kirkwood

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

263-271

1 reference

16 August 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Cancer immunotherapy: the interferon-alpha experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

The role of Bcl-2 family members in the progression of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Induction of apoptosis by G3139 in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Targets for molecular therapy of skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

21 January 2018

Mechanisms of apoptosis

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.263

Systemic treatments for metastatic cutaneous melanoma.

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001215

Identifiers

DOI

10.2217/14796694.3.3.263

1 reference

16 August 2017

1 reference